Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 365

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 365
---
 expenses. Other general and administrative expenses may also include professional fees for patents, insurance costs and board of directors’ expenses.

We anticipate that our general and administrative expenses will increase in the future as we continue to support research and development activities and incur increased costs of operating a public company. These costs include increased headcount to support expanded operations and infrastructure, and the initiation, continuation and expansion of our preclinical studies and clinical trials for our product candidates. Additionally, we anticipate increased costs associated with maintaining compliance with Nasdaq rules and SEC requirements such as accounting, audit, legal and consulting services, as well as director and officer liability insurance, investor and public relations activities.

### Results of Operations
Nine months ended September 30, 2024 Compared to the Nine months ended September 30, 2023

General and Administrative Expenses

General and administrative expenses were $0.5 million for the nine months ended September 30, 2024 as compared to $1.0 million for the nine months ended September 30, 2023. The decrease of $0.5 million was primarily related to decreases in accounting and legal costs related to the Business Combination and general corporate matters during the nine months ended September 30, 2024 as compared to nine months ended September 30, 2023.

Research and Development Expenses

Research and development expenses were $2.7 million for the nine months ended September 30, 2024 as compared to $3.0 million for the nine months ended September 30, 2023. The decrease of $0.3 million was primarily related to decreased spending for preclinical and clinical trials for both the CAR-T products and the GCC vaccine products because of the termination of the CAR-T License and Vaccine License.

Year Ended December 31, 2023 Compared to Year Ended December 31, 2022

General and Administrative Expenses

General and administrative expenses were $1.1 million for the year ended December 31, 2023 as compared to $0.9 million for the year ended December 31, 2022 for an increase of $0.2 million primarily related to accounting expenses and other transaction costs incurred related to the Business Combination and corporate matters.

Research and Development Expenses

Research and development expenses increased by $1.9 million during the year ended December 31, 2023 as compared to the year ended December 31, 2022, from $1.9 million for the year ended December 31, 2022 to $3.8 million